Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
08 November 2024 - 2:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of November 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
EXHIBIT INDEX
|
Exhibit No.
|
Description
of Exhibit
|
|
99.1
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: November 08,
2024
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
Indivior Responds to Publication
of a Letter by Oaktree Capital Management to the Board of
Indivior
Richmond, VA, November 8, 2024 - Indivior PLC (NASDAQ / LSE: INDV)
the Board of Directors (the
"Board") of Indivior plc ("Indivior" or the "Company") notes the
publication today of a letter from Oaktree Capital Management LP
("Oaktree") to the Board of Indivior.
The Board has engaged actively with Oaktree in recent weeks on
these topics, and remains open-minded about all proposals to
enhance value creation. The Board is focused on acting in the best
interests of all shareholders as we continue to execute on our
strategy.
Indivior looks forward to further engagement with
Oaktree and other shareholders.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD), overdose and serious mental illnesses. Our vision
is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and
co-occurring disorders of SUD. Indivior is dedicated to
transforming SUD from a global human crisis to a recognized and
treated chronic disease. Building on its global portfolio of OUD
treatments, Indivior has a pipeline of product candidates designed
to both expand on its heritage in this category and potentially
address other chronic conditions and co-occurring disorders of SUD.
Headquartered in the United States in Richmond, VA, Indivior
employs over 1,000 individuals globally and its portfolio of
products is available in over 30 countries worldwide.
Visit www.indivior.com to
learn more. Connect with Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
For Further Information
|
Investor Enquiries
|
Jason Thompson
|
VP,
Investor RelationsIndivior PLC
|
+1
804 402 7123
jason.thompson@indivior.com
|
|
|
|
Tim Owens
|
Director,
Investor Relations Indivior PLC
|
+1
804 263 3978
timothy.owens@indivior.com
|
|
Media Enquiries
|
Jonathan Sibun
|
Teneo
U.S.
Media Inquiries
|
+44
(0)20 7353 4200
+1
804 594 836
Indiviormediacontacts@indivior.com
|
Indivior (NASDAQ:INDV)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Indivior (NASDAQ:INDV)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
